Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
The Prostate, 06/30/09
Festuccia C et al. - In a study to determine why EGFR inhibitors been so ineffective in human prostate cancer (PCa), the results seem to suggest that a low EGFR/Her2 ratio and PTEN absence are the main factors responsible of erlotinib inefficacy. The inhibition of EGFR could have important antitumor effects in hormone-naive rather than in hormonally treated pts.
Methods- The effectiveness of erlotinib was assessed in a wide range of PCa cells (wild type or engineered to overexpress peculiar proteins including androgen receptor and PTEN).
- The effectiveness of erlotinib was inversely correlated to the EGFR/Her2 ratio rather than EGFR/p-EGFR or Her2/p-Her2 levels.
- Chronic treatment with bicalutamide induced overexpression of Her2 and reduction of EGFR/Her2 ratio and this was associated with increased Akt and Erk activity.
- In these treatment conditions, a reduced efficacy of erlotinib was observed.
- At the same time, an increased efficacy vs erlotinib was documented in cancer cells chronically exposed to DHT.
- In these culture conditions, low levels of Her2 and increased EGFR/Her2 ratio were evidenced.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Article Search
Sponsor


See Latest Articles


